Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes
Advances and next-generation incretin therapies The expansion of this class of medications is moving rapidly, and this is likely just the beginning
your doctor should review all current medicines [16] [17] Realistic expectations for weight loss , including the likelihood of weight regain if treatment is discontinued a pattern observed with other medicines in this class Long-term commitment and monitoring requirements , including regular blood tests (including renal function, HbA1c, and liver enzymes), cardiovascular assessments, and follow-up appointments Pregnancy, breastfeeding, and contraception : Weight-loss medicines are not recommended during pregnancy or breastfeeding
Review VivioMD's current program and eligibility information VivioMD GLP-1 Fast Facts Service type: telehealth GLP-1/GLP-1+GIP weight-care program - according to VivioMD as of July 2026 Platform entity: VivioMD Group LLC, 16192 Coastal Highway, Lewes, DE 19958 Medical group: OpenLoop Healthcare Partners P.C